This could fly. They’re launching a potentially highly lucrative B2C product (fast deployment, higher margin) at the same time as securing US FDA, which helps B2B and B2C products - globally, given the credentials of FDA.
It is a great way to get fast, signficant momentum (exposure, media, revenue, share price). Which all feed on each other.
A very exciting number of weeks ahead.
Ann: PainChek appoints head of Business Development for US market, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
3.7¢ |
Change
-0.003(7.50%) |
Mkt cap ! $68.15M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.7¢ | $65.06K | 1.718M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 255277 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.7¢ | 124419 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| PCK (ASX) Chart |